Moderna RSV Vaccine Shows 81.8% Hospitalization Protection

A JAMA Network Open study of older US veterans found the mResvia vaccine's protection against RSV-related hospital stays was strongest in younger recipients.

Updated on Nov. 11, 2026 in Asthma

Moderna RSV Vaccine Shows 81.8% Hospitalization Protection

Live Poll

Would you trust a new RSV vaccine to protect you from hospitalization?

A study published in JAMA Network Open found Moderna's mResvia RSV vaccine was 81.8% protective against RSV-associated hospitalizations among older US veterans. Protection against documented infections was 60.3%, and effectiveness declined with age.

Why it matters

The findings add real-world evidence on how well the vaccine performs outside clinical trials, which can inform decisions by older adults and clinicians about RSV prevention. The age-related drop in protection highlights a gap for the oldest recipients.

The study compared 74,926 vaccinated veterans with 286,425 matched unvaccinated controls over 24 weeks. Effectiveness against documented infections fell from 82.9% in ages 50 to 59 to 28.6% in ages 80 and older, and how long protection lasts across multiple seasons remains unestablished.

The players

Moderna

Moderna is a biotechnology company that developed the mResvia RSV vaccine using messenger RNA technology.

The details

Researchers used a target trial framework to assess veterans aged 50 and older receiving care in the Veterans Health Administration, matching each vaccinated person with up to four unvaccinated people across four monthly nested trials. The vaccine was approved by the FDA in May 2024 for adults 60 and older and expanded in June 2025 to adults 18 to 59 at increased risk.

Timeline

  1. May 2024: FDA approves the vaccine for adults 60 and older.

  2. June 2025: FDA expands approval to adults 18 to 59 at increased risk.

  3. October 1, 2025 to January 31, 2026: Study period for veterans receiving VA care.

  4. 24 weeks: Follow-up period for study participants.

Health Landscape

The FDA's May 2024 approval of mResvia for adults 60 and older, expanded in June 2025 to adults 18 to 59 at increased risk, set the regulatory framework this real-world study now tests. The findings show protection against hospitalization remaining high while infection protection declines in the oldest recipients.

For adults 60 and older, and younger adults at increased risk, the study suggests the vaccine substantially reduces the chance of RSV-related hospital care. Protection against mild infection is more modest and drops with age, so clinicians may weigh that trade-off in discussions about vaccination.

The takeaway

The vaccine appears most protective against severe outcomes, such as hospitalization, which matters most for older adults. Anyone eligible should discuss RSV vaccination with a clinician to weigh their age and risk factors.

Further reading

Explore more on Asthma and related respiratory illness coverage.

Live Poll

Would you trust a new RSV vaccine to protect you from hospitalization?